edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: AdAlta
Edison Investment Research is terminating coverage on AdAlta. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
AdAlta — 1 video in collection
AdAlta is an Australian healthcare company focused on using its proprietary i-body discovery platform to target diseases, with an initial focus on conditions involving fibrosis. Its lead programme is AD-214 for the treatment of idiopathic pulmonary fibrosis, currently in Phase I. AdAlta has also licensed its platform to GE Healthcare for the purpose of diagnostic imaging.
In this interview, CEO Tim Oldham provides an overview of the company’s programmes and reviews the recently announced clinical data for AD-214 as well as the company’s partnership strategy.
Get access to the very latest content matched to your personal investment style.